AbCellera Biologics Inc. (ABCL)

NASDAQ: ABCL · Real-Time Price · USD

3.610

+0.020 (0.56%)

At close: Feb 27, 2026, 4:00 PM EST

3.700

+0.090 (2.50%)

After-hours: Feb 27, 2026, 7:59 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Discovery and Development of Antibodies				485.42M	375.20M	233.16M	11.61M	8.83M
Discovery and Development of Antibodies Growth				29.38%	60.92%	1907.88%	31.49%	-
Total				485.42M	375.20M	233.16M	11.61M	8.83M
Total Growth				29.38%	60.92%	1907.88%	31.49%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Canada				485.42M	375.20M	233.16M	11.61M	8.83M
Canada Growth				29.38%	60.92%	1907.88%	31.49%	-
Total				485.42M	375.20M	233.16M	11.61M	8.83M
Total Growth				29.38%	60.92%	1907.88%	31.49%	-

Source: S&P Global Market Intelligence.